Rauch H, Fleischer F, Böhrer H, Jürs G, Wilhelm M, Krier C
Department of Anaesthesia, University of Heidelberg, FRG.
Intensive Care Med. 1989;15(2):84-6. doi: 10.1007/BF00295982.
We studied the serum aluminum levels of 30 intensive care patients receiving six daily doses of magaldrate (Riopan) or aluminium hydroxide (Trigastril). In both groups we found a significant rise of the serum aluminium concentration (p less than 0.01) following administration of the antacid solutions. Examination on day 9 and 15 the magaldrate group showed significantly (p less than 0.05) lower aluminium levels than the aluminium hydroxide group. An increase up to the critical serum aluminium level of 100 ng/ml occurred in none of the patients that all had normal or slightly impaired renal function. Therefore routine measurements of serum aluminium levels in patients without renal impairment are not considered necessary following antacid therapy. However, we recommend the use of antacids with an aluminium absorption rate as low as possible.
我们研究了30例重症监护患者的血清铝水平，这些患者每天接受6次剂量的氢氧化铝镁（乐得胃）或氢氧化铝（胃可舒）治疗。在两组中，我们发现服用抗酸剂溶液后血清铝浓度显著升高（p<0.01）。在第9天和第15天检查时，氢氧化铝镁组的铝水平显著低于氢氧化铝组（p<0.05）。所有肾功能正常或轻度受损的患者均未出现血清铝水平升高至临界值100 ng/ml的情况。因此，对于肾功能未受损的患者，抗酸治疗后无需常规检测血清铝水平。然而，我们建议使用铝吸收率尽可能低的抗酸剂。
